FDA Approves Ivermectin Lotion to Treat Head Lice

Pharmacy TimesAugust 2021
Volume 87
Issue 8
Pages: 70

The FDA has approved ivermectin 0.5% (Sklice; Arbor Pharmaceuticals) lotion for OTC use for the treatment of head lice. Ivermectin 0.5% was initially approved in February 2012 for prescription use in patients 6 months and older.

Every year, approximately 6 million to 12 million cases of head lice occur in children aged 3 to 11 years in the United States.

Head lice are most common among preschool children in childcare, elementary school children, and members of a household in which children have lice.

Ivermectin 0.5% is for external use only and should be used on dry hair or the scalp in accordance with label instructions. The FDA has not approved the lotion for any other use.

The lotion will be marketed as a nonprescription drug and will no longer require
a prescription.

According to the FDA, those using a prescription version of the product should consult their health care professionals.


FDA Approves Lotion for Nonprescription Use to Treat Head Lice [News Release] October 27, 2020; White Oak, MD. https://www.fda.gov/news-events/press-announcements/fda-approves-lotion-nonprescription-use-treat-head-lice?utm_medium=email&utm_source=govdelivery. Accessed October 28, 2020

Related Videos
Pride flags during pride event -- Image credit: ink drop | stock.adobe.com
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.